Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept for Bullous Pemphigoid (Real-World Observational Study)
ChiCTR2500106895Phase 4Recruiting
- Sponsor
- Shandong First Medical University Affiliated Dermatology Hospital
- Start
- Jul 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of telitacicept in Bullous Pemphigoid (BP), sponsored by Shandong First Medical University Affiliated Dermatology Hospital. Primary endpoints: Complete remission off therapy at 52 weeks and Pathogenic antibody negativity rate and time to negativity at 52 weeks. Started Jul 2025; status: recruiting.
02
Drugs
telitacicept
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on ChiCTR2500106895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106895.